Background
==========

Since the first outbreak of a respiratory illness caused by Influenza A (H1N1) virus in Mexico \[[@B1]\], several reports have described the need of intensive care \[[@B2]-[@B4]\] or extracorporeal membrane oxygenation (ECMO) assistance \[[@B5]\] in young and often healthy patients.

Beginning August 2009, the Italian Ministry of Health and the Tuscany Ministry of Health issued instructions to identify and establish referral centers able to care for the more severely ill influenza patients. Therefore, several referral centers were identified throughout the national territory among the hospitals already experienced in extracorporeal respiratory support techniques. The referral ECMO centres, in addition to being capable of guaranteeing the most advanced treatment in influenza related respiratory failure, were also entrusted with providing support to the nearby hospitals and assuring safe transportation.

In the present investigation we report our experience, as an ECMO referral center, in H1N1-induced acute respiratory distress syndrome (ARDS) and we present the critical care service planning in response to the H1N1 pandemic.

Methods
=======

Following the instructions of the Italian Ministry of Health and Tuscany Regional Ministry of Health, an Emergency Medical Service was established in the Careggi Hospital in Florence Italy for the novel pandemic influenza.

The Careggi Hospital ECMO Team is composed of: an intensivist, a cardiac surgeon, a cardiologist, a nurse, and a perfusionist. All of the members of the team are properly trained in ECMO treatment. An ambulance and a car are equipped with an ECMO circuit, a transport ventilator and all of the materials needed to initiate extracorporeal support in the peripheral hospitals, and permit safe transportation while on extracorporeal circulation to our referral hospital.

The requirement of ECMO was decided based on the Italian Ministry of Health criteria (Table [1](#T1){ref-type="table"}).

###### 

Italian Ministry of Health criteria to discuss the need of ECMO.

  **Acute respiratory failure with one of the following condition**:
  ----------------------------------------------------------------------------------------------------
  1\. SaO~2~\< 85% for at least 1 hour
  2\. Oxygenation Index \>25 for at least 6 hours after ventilation optimisation
  3\. PaO~2~/FiO~2~\< 100 with PEEP ≥ 10cmH2O for at least 6 hours after ventilation\'s optimization
  4\. Hypercapnia with pH \< 7.25
  5\. SvO~2~\< 65% with hematocrit \>30 and under vasoactive drugs infusion

The parameter are referred to a condition of lung protective ventilation (tidal volume:4-6 ml/Kg of predicted body weight; plateau pressure ≤ 30 cmH~2~0; PEEP \>lower inflection point of the curve pressure-volume).

PEEP: positive end-expiratory pressure; PaO~2~: arterial oxygen partial pressure; FiO~2~: inspired oxygen fraction; RR: respiratory rate; SaO~2~: peripheral oxygen saturation; SvO~2~: central venous oxygen saturation.

Oxygenation Index: Mean airway pressure (cmH~2~O) \* FiO~2~\* 100/PaO~2~;

From September 2009 to January 2010, all patients admitted to our ICU with severe respiratory failure due to H1N1 infection were included in this study. Patient demographics and clinical characteristics were collected from institutional ICU database (FileMaker Pro, FileMaker, Inc, USA), from Italian Group for the Evaluation of Interventions in Intensive Care Medicine database (GiViTI Margherita Project, Istituto Mario Negri, Bergamo, Italy) and from ECMO national network database. Discrete variables are expressed as counts and percentages, whereas continuous variables are reported as medians with 25th to 75th interquartile range (IQR). The Internal Review Board approved this retrospective study and informed consent for data publication was obtained from the patients or relatives.

Ventilation strategy
--------------------

Pressure volume curves were calculated with ventilator\'s built in application (Draeger Evita XL, Draeger Medical AG, Lubeck Germany) starting from a PEEP level of 5 cm H~2~O, with a pressure limit of 40. Ventilation parameters were set on the basis of this calculation, with a PEEP of 2 cmH~2~O above the lower inflection point of the pressure-volume curve, and a peek pressure below the upper inflection point. In all cases, pressure plateau was limited to 30 cmH~2~O and the tidal volume was kept below 6 ml/Kg \[[@B6]\]. Recruitment manoeuvres (40 sec at 40 cmH~2~O) were performed twice a day, if needed, to improve pulmonary gas exchange.

ECMO
----

All ECMO treatments were veno-venous (Maquet Rotaflow Centrifugal Pumps with Quadrox-D oxygenators, Maquet, Rastatt, Germany) and biocoated circuits were used.

Two types of cannulation were used. Initially a venous withdrawal cannula was inserted via femoral vein (Edwards Lifesciences Femoral Venous Cannula 22-24 Fr., Edwards Lifescience, Irvine, CA-USA or Maquet HLS Venous Cannula 21-25 Fr., Maquet Cardiopulmonary AG, Hirrlingen-Germany) and an infusion cannula in the right jugular vein (Edwards Lifesciences Fem-Flex II Cannula 20 Fr., Edwards Lifescience, Irvine, CA-USA or Maquet HLS Arterial Cannula 23 Fr., Maquet Cardiopulmonary AG, Hirrlingen-Germany) were adopted. During the period study Avalon double lumen cannulas (Avalon Elite Bi-Caval Dual Lumen Catheter 27-31 Fr., Avalon Laboratories, Rancho Dominguez, CA - USA) become available and were inserted through internal right jugular vein in 2 patients.

Cannulation was conducted percutaneously with Seldinger technique in all cases, and cannulas position was confirmed by transesophageal echocardiography.

Heparin infusion during extracorporeal lung assistance was monitored every two hours by bedside aPTT measurement (Hemochron Jr. Signature plus, ITC Europe, Milan, IT), which was maintained between 50 and 80 seconds. In case of renal replacement therapy requirement in ECMO patients, a continuous veno-venous hemodiafiltration circuit was assembled on the ECMO circuit (aspiration on pre-pump line, restitution on pre-oxygenation line).

ECMO patients were ventilated with protective parameters, and respiratory rate and ECMO flow were adjusted to achieve normocarbia and oxygen saturation above 92%.

Infection control
-----------------

H1N1 infection was confirmed by real-time reverse transcriptase-polymerase-chain-reaction (RT-PCR) assayed on pharyngeal swab, subglottic aspiration and bronchoalveolar lavage in accordance with published guidelines \[[@B7]\]. Bronchoalveolar specimens were obtained with a mini-invasive system (Kimberly-Clark BAL Cath, Kimberly-Klark N.V. Zaventem - Belgium), or by bronchoscopy.

Patients were isolated in negative pressure atmosphere rooms, and staff wore full protective garments (including FFP3 respirators, 3 M Italia SpA, Segrate, Italy), until 2 consecutive tests were confirmed negative. During the study period only one case of suspected transmission of influenza to a nurse occurred.

Antiviral therapy consisted in oral oseltamivir (75 mg twice daily) and inhaled zanamivir (10 mg twice daily).

Blood and urinary cultures, tracheal aspirate, and pharyngeal swab were obtained upon patient admission. Empiric antimicrobial regimen at ICU admission was initiated with levofloxacin and amoxicillin/clavulanate; eventually specific antimicrobial therapy was varied or ended on the basis of microbiological results.

Steroids were administered at low dosage (20 mg metilprednisolon twice per day) to prevent lung fibrosis. Diuretics were administered at different dosages, depending on clinical judgment and the patient\'s renal function.

Lung ultrasound examination
---------------------------

Lung ultra sound (LUS) examinations were daily performed by the attending physician, with a multi-frequency convex probe (3.5-5 MHz, Mylab TM 30CV, ESAOTE, Genova, IT). With the patient in semirecumbent position, lateral and anterior views were obtained from base to apex of the chest. Posterior axillary line was followed during lateral transversal examinations. Chest quadrants defined by the intercostal spaces and the parasternal, mid-clavicular, and anterior axillary lines were scanned on the anterior chest wall \[[@B8]\]. The occurrence and extension of parenchymal consolidations, alveolar interstitial syndrome (measured by the number of B-lines), and morphology of pleural line were evaluated \[[@B9]-[@B11]\]. Pleural effusions were estimated by using Balik\'s formula \[[@B12],[@B13]\]. In order to ensure a uniform record, and allow to follow the evolution of the findings over time, all exams were recorded in an electronic form, in which the description of the main LUS features was predetermined \[[@B14]\].

Results
=======

Overall patients
----------------

During the study period, 12 patients requiring invasive ventilation treatment and/or ECMO were admitted or transferred to our ICU. Baseline and clinical characteristics of patients admitted for H1N1-induced severe respiratory failure are summarized in Table [2](#T2){ref-type="table"}.

###### 

baseline and clinical characteristics of H1N1-pneumonia patients.

  Number                                          12
  ----------------------------------------------- ----------------------
  **Male sex, N (%)**                             8 (66 .7%)
                                                  
  **Age (years)**                                 44.5 (36.8-48.8)
                                                  
  **BMI**                                         27 (23.8-31)
                                                  
  **SAPS II**                                     36 (27.75-44.75)
                                                  
  **Patients with comorbidities, N (%)**          5 (41 .7%)
                                                  
  **Patients with proved coinfection, N (%)**     2 (16 .7%)
                                                  
  **Days from onset to ICU admission**            7 (6-8.25)
                                                  
  **§ PaO**~**2**~**(mmHg)/FiO**~**2**~           92 (53.5-119.5)
                                                  
  **§ PaCO**~**2**~**(mmHg)**                     65 (39.9-83)
                                                  
  **§ pH**                                        7.37 (7.32-7.50)
                                                  
  **§ Respiratory rate (N/min)**                  8.62 (6.87-11.3)
                                                  
  **§ White cells count (N\*1000/ml)**            8.620 (6.870-11.300)
                                                  
  **§ Platelets count (N\*1000/ml)**              158.5 (102-217.3)
                                                  
  **§ Lactate dehydrogenase (U/l)**               617 (391.2-919.8)
                                                  
  **§ Creatine kinase (U/l)**                     611 (402.5-893.8)
                                                  
  **§ Aspartate aminotransferase (U/l)**          53.5 (39.8-121.3)
                                                  
  **§ Alanine aminotransferase (U/l)**            37.5 (27.3-43.5)
                                                  
  **§ C-reactive protein (mg/dl)**                80.5 (35.9-132.4)
                                                  
  **§ Serum creatinine (mg/dl)**                  0.87 (0.69-1.26)
                                                  
  **§ Procalcitonin (ng/ml)**                     3.2 (1.1-4.3)
                                                  
  **Chest radiographs**(mean per patient)         7.3
                                                  
  **Chest CT-scan**(mean per patient)             1.25
                                                  
  **Tracheostomy, N (%)**                         5 (41 .7%)
                                                  
  **ECMO, N (%)**                                 7 (58 .3%)
                                                  
  **CVVH, N (%)**                                 2 (16 .7%)
                                                  
  **Duration of mechanical ventilation (days)**   13.5 (10.8-21.5)
                                                  
  **ICU lenght of stay (days)**                   16.5 (10.5-25.5)
                                                  
  **Mortality, N (%)**                            1 (8 .3%)

Data are referred to first assessment at ICU admission. Continuous data are represented as medians with 25th to 75th interquartile range (IQR). Percent data are referred to the total population of each group.

BMI: body mass index; CVVH: continuous veno-venous hemofiltration; ECMO: extracorporeal membrane oxygenation; SAPS: simplified acute physiology score.

§ values at ICU admission

The median time between initial, non specific, symptoms and respiratory failure was 7 days (IQR 6-8.25), and severe hypoxia, unresponsiveness to non-invasive ventilation, was the main clinical feature. Our patients were young, median age 44.5 years, none of them older than 58 years, and eight (80%) younger than 50. Two patients were severely obese (BMI \> 40), one woman was pregnant (18 weeks), two patients had a history of chronic obstructive respiratory disease (COPD), and one had diabetes. Two patients had Legionella Pneumophila coinfection at admission, and one young patient (16 years old) with suspect viral myocarditis and heart failure. At admission the patients, with the exception of the two coinfected, presented low leukocyte and platelet count and low plasma procalcitonin levels, significant levels of lactate dehydrogenase (LDH), creatine kinase (CK), and C-reactive protein (Table [2](#T2){ref-type="table"}). Median duration of mechanical ventilation (days) was 11.5 (IQR 9.8-16.3) and median ICU length of stay (days) was 14 (IQR 12-16.5). The pregnant woman continued the pregnancy without significant complications.

In ICU infection rate was low with two ventilator associated pneumonia and two asymptomatic positive blood cultures in two ECMO patients. One ECMO patient died due to a systemic secondary infection by Aspergillus: this patient was the only non-surviving patient (overall mortality rate 8.3%).

H1N1 infection monitoring and therapy
-------------------------------------

RT-PCRs from bronchoalveolar lavage samples were positive in all patients included in this study. On the contrary, RT-PCR dosed on pharyngeal swab resulted positive in less than 70% of patients at ICU admission, and in 90% of patients in the second day (Figure [1](#F1){ref-type="fig"}). Also efficacy of antiviral therapy was reliably followed through RT-PCR from bronchoalveolar samples, since analysis on pharyngeal swabs became negative quite early. Finally, no RT-PCR significant for H1N1 infection from subglottic aspirate sample was found.

![Time course of RT-PCR results on pharyngeal swab and bronchoalveolar lavage.](1471-2466-11-2-1){#F1}

In one patient, intravenous administration of zanamivir was needed, since the patient remained positive to viral infection after two weeks of therapy. Intravenous formulation of zanamivir is still subjected to pre-phase 4 clinical trial investigation, even if some reports on its safety profile are already available in literature. Therefore, local Ethical Committee approval was requested and the manufacturer provided the drug for use. Zanamivir was administered intravenously for five days (600 mg twice daily), as indicated by the producer. The patient\'s respiratory function improved and RT-PCR became negative after the third day. No adverse reaction was noted.

Lung ultrasound (LUS) examination in H1N1-induced ARDS
------------------------------------------------------

A total of 156 LUS have been performed. During every LUS, the following parameters were considered: pleural line aspect and motility, presence of consolidations, occurrence and severity of Alveolar Interstitial Syndrome (based on the number of B-lines), presence of pleural effusion and occurrence of pneumothorax.

Pleural thickness was described in 100% of cases and mostly bilaterally. Lung base was always involved. Lung gliding was present in 70% of LUS, even if decreased (20%). Pathological Lung Pulse was found in 20% of LUS, often in proximity to large parenchyma consolidations. Pleural effusion occurred in 7 patients. Two spontaneous pneumothorax have been detected with LUS during ICU treatment.

Alveolar Interstitial Syndrome was present in all ultrasound examinations, with the presence of normal lung pattern (spared areas). In 90% of cases, B-Lines were described as moderate/many. At lung recovery, residual B-Lines patterns were found mostly at both bases. White lung feature occurred in about 15% of LUS performed, mostly in the anterior and lateral scans. White lung was never uniformly distributed, but it was alternated to spared areas, or areas with a limited number of B-Lines.

Consolidations were found in 100% of cases. Most of them were multiple (65%), and lung bases were always involved. Contiguous subpleural consolidations were also present, increasing the pleural thickness laterally, mostly at the base and the apical part. Aerial bronchograms were always found within the consolidation pattern.

The routine use of LUS limited the number of conventional radiology examinations (Table [3](#T3){ref-type="table"}). In ECMO patients group, the higher number of chest X-ray examinations was needed to verify the correct cannulae positioning. In both groups, bedside LUS limited the transportation to the CT-scan room, increasing patient safety and avoiding the transitory disconnection of the patient from the ventilator.

###### 

differences between ECMO and ventilated patients.

                                                  ECMO patients       Non-ECMO patients
  ----------------------------------------------- ------------------- ---------------------
  **Number (%)**                                  7                   5
                                                                      
  **Male sex, N (%)**                             6 (85 .7%)          2 (40%)
                                                                      
  **Age (years)**                                 45 (37-46.5)        42 (39-51)
                                                                      
  **BMI**                                         27 (23.5-36.5)      27 (25-29)
                                                                      
  **SAPS II**                                     44 (39-50.5)        28 (27-28)
                                                                      
  **Patients with comorbidities, N (%)**          5 (71 .4%)          2 (40%)
                                                                      
  **Patients with proved coinfection, N (%)**     2 (28 .6%)          0
                                                                      
  **Days from onset to ICU admission**            6 (6-7.5)           7 (7-9)
                                                                      
  **§ PaO**~**2**~**(mmHg)/FiO**~**2**~           48.7 (46.8-58)      116 (107-141)
                                                                      
  **§ PaCO**~**2**~**(mmHg)**                     81.6 (60.6-88)      57 (55.8-63)
                                                                      
  **§ pH**                                        7.25 (7.20-7.30)    7.33 (7.28-7.34)
                                                                      
  **§ Respiratory rate (N/min)**                  10 (8.5-15)         20 (18-22)
                                                                      
  **§ PEEP (cmH**~**2**~**O)**                    14 (11-15)          14 (11-15)
                                                                      
  **§ Static compliance(ml/cmH**~**2**~**O)**     34 (30-38)          32 (23-38)
                                                                      
  **§ White cells count (N\*1000/ml)**            11 (9.1-13.3)       7.03 (6.7-8.6)
                                                                      
  **§ Platelets count (N\*1000/ml)**              151 (115.5-218.5)   158.5 (125.3-182.5)
                                                                      
  **§ Lactate dehydrogenase (U/l)**               445 (372.5-920.5)   627 (607-632)
                                                                      
  **§ Creatine kinase (U/l)**                     477 (189-890.3)     435 (281.5-695)
                                                                      
  **§ Aspartate aminotransferase (U/l)**          54 (42-121.5)       53 (42-78)
                                                                      
  **§ Alanine aminotransferase (U/l)**            38 (25.5-41)        37 (29-45)
                                                                      
  **§ C-reactive protein (mg/dl)**                83.5 (77.5-315.7)   127.5 (96.3-158.8)
                                                                      
  **§ Serum creatinine (mg/dl)**                  1.02 (0.79-1.72)    0.81 (0.55-0.85)
                                                                      
  **§ Procalcitonin (ng/ml)**                     4.3 (2.7-29.4)      1.9 (0.2-2.6)
                                                                      
  **CVVH, N (%)**                                 2 (28 .6%)          0
                                                                      
  **Chest radiographs (mean per patient)**        9.6                 4.2
                                                                      
  **Chest CT-scan (mean per patient)**            1.6                 0.8
                                                                      
  **Duration of mechanical ventilation (days)**   19 (12-36)          9 (5-11)
                                                                      
  **ICU lenght of stay (days)**                   23 (17.5-38)        11 (8-14)
                                                                      
  **Packed Red Blood Cells Units, N**             4 (1-6)             1 (0-3)
                                                                      
  **Mortality, N (%)**                            1 (14.3%)           0 (0%)

Data on airway pressures and respiratory rate are referred after intubation and recruitment. Continuous data are represented as medians with 25th to 75th interquartile range (IQR). Percent data are referred to the total population of each group.

BMI: body mass index; CVVH: continuous veno-venous hemofiltration; ECMO: extracorporeal membrane oxygenation; SAPS: simplified acute physiology score.

§ Values at ICU admission

ECMO patients
-------------

ECMO was needed in 7 patients (Table [3](#T3){ref-type="table"}). In 4 cases, the ECMO Team was alerted and extracorporeal oxygenation was implanted directly at peripheral ICUs. No major transportation related problems were faced, even in the case of a long distance journey (400 Km). Median duration of ECMO support was 8 days (IQR 6-16.5), with a median duration of mechanical ventilation (days) of 19 (IQR 12-36).

Main clinical features and ventilatory and ECMO parameters of patients treated with ECMO are presented in Table [4](#T4){ref-type="table"}. Bleeding was the most important complication. In three cases, bleeding from vascular access sites due to heparin infusion required blood transfusions. Three patients presented prolonged oropharyngeal bleeding and transfusions were required. Among them, one needed electrical coagulation of a palatine injury, probably related to nursing manoeuvres. Two patients presented severe intra-bronchial bleeding, and several flexible bronchoscopy examinations and clot suctions were required. In one of these patients, bleeding from the lower airways during the weaning phase from ECMO, and ECMO removal has been hastened.

###### 

main ventilation and ECMO data of patients treated with ECMO

                                                              Pre-ECMO parameters        In-ECMO parameters (Day 1)                                                                   
  -------------- ---- --------------------------------------- --------------------- ---- ---------------------------- ---- ---- ---- ------ --- ---- ---- ----- ---- ----- ---------- ------
  **1**          15   Asthma                                  30                    14   350                          14   50   52   7.18   1   18   10   300   10   5.2   6          3
                                                                                                                                                                                      
  **2**          58   \-                                      30                    14   400                          16   66   76   7.14   2   22   14   300   7    5.0   6          5
                                                                                                                                                                                      
  **3**^**§**^   44   Obesity                                 33                    15   240                          20   60   89   7.27   2   28   15   200   9    6.1   15\^       12
                                                                                                                                                                                      
  **4**^**§**^   48   Cigarette smoke                         40                    10   700                          18   58   54   7.29   1   24   14   270   7    5.9   8          10\^
                                                                                                                                                                                      
  **5**^**§**^   30   Asthma, obesity, cigarette smoke        35                    15   700                          22   48   55   7,22   2   24   14   400   6    5.3   6          3
                                                                                                                                                                                      
  **6**^**§**^   45   Psychiatric disorder, emphysema bulla   45                    18   250                          20   54   73   7.22   6   28   17   160   8    5.7   37^\#^\^   \-
                                                                                                                                                                                      
  **7**          45   \-                                      35                    15   410                          32   73   84   7.17   7   25   15   300   20   5.0   18         21\^

PEEP: positive end expiratory pressure; RR: respiratory rate; tV: tidal volume.

\* Measured with FiO2 = 1

§ Patient referred from another hospital

\# Dead on ECMO

\^ patient tracheostomized during ECMO

Table [3](#T3){ref-type="table"} summarizes the main differences between patients who underwent to ECMO treatment and patients only ventilated. Despite the small sample, ECMO patients clearly showed a higher critical illness score (SAPS II), and worst pulmonary gas exchange compared to patients who did not required extracorporeal lung assistance. Coinfection and comorbidities at admission were present only in ECMO patients.

Discussion
==========

Our study population is young, comprising mainly healthy subjects, as previously reported \[[@B1],[@B2],[@B15]\]. Risk factors are similar to other studies, such as obesity, diabetes and pregnancy.

In the present case series, bacterial infection rate at presentation was low. Previous reports showed incidence of secondary superinfection by Streptococcus Pneumoniae, Staphylococcus Aureus, Pseudomonas Aeruginosa, Acinetobacter Baumannii, Escherichia coli \[[@B1],[@B3],[@B2]\]. In our experience, we found two cases (16.7%) of co-infection with Legionella Pneumophila, which is, to the best of our knowledge, a new epidemiological data, since no other case has been reported in literature. It is questionable whether Legionella Pneumophila infection occurred before or after H1N1 pneumonia. However, it could be that H1N1 pneumonia was associated with a lower reactivity of the immune system, as suggested by the low leucocytes count reported in our sample and by other Authors \[[@B3],[@B2],[@B1]\].

One young patient presented heart failure, and viral myocarditis was suspected. The association of influenza with myocarditis is debated \[[@B16]\], and H1N1 related myocarditis, has rarely been reported \[[@B17]\]. Furthermore, in our patient prolonged pre-hospital hypoxia was present and myocardial hypoxemia damage might have been involved. The patient required inotrope/vasoactive support for several days and eventually recovered fully with normal heart function.

Our observations confirm the responsiveness of this infection to antiviral therapy. We adopted a two-modality administration, both oral and inhaled. Our choice was made in consideration of the decrease in gut motility and adsorption usually observed in critically ill patients.

The World Health Organization (WHO) has questioned the sensibility of RT-PCR analysis for H1N1 in pharyngeal swab sample, encouraging analysis on samples from the lower respiratory tract. We routinely monitor H1N1 infection on three compartments: pharyngeal swab, subglottic aspiration, and bronchoalveolar lavage. In our experience, bronchoalveolar lavage at admission was positive in all patients while pharyngeal swab resulted positive in only 75% of cases.

As shown in Figure [1](#F1){ref-type="fig"}, RT-PCR from pharyngeal swab at ICU admission failed to demonstrate the viral infection in 3 patients. Similarly, the time course showed that RT-PCR from pharyngeal swab resulted negative in an average time of 3 days after therapy start. Conversely RT-PCRs from bronchoalveolar lavage remained positive for a longer period and resulted more reliable for infection monitoring and assessment of the efficacy of administered therapy.

Based on our experience, RT-PCR from bronchoalveolar lavage resulted to be the most reliable method to diagnose and monitor H1N1 infection, since pharyngeal swab does not offer enough sensibility, neither for antiviral therapy initiation nor for antiviral therapy management. As subglottic aspiration resulted persistently negative, we do not recommend this sampling for diagnosis and monitoring of H1N1 infection.

Despite the severe clinical pictures, we experienced a very low mortality rate: only one patient out of 12 died (8,3%). One of the surviving patients presented a lung cavern for a past pulmonary infection, and deceased for a secondary superinfection by Aspergillus, probably already colonizing lung parenchyma before the onset of viral infection.

Our mortality rate is surprisingly low in comparison to a larger series of H1N1 patients, even when extracorporeal support technique were employed \[[@B5],[@B18]\]. Our finding can be related to the small number of patients included the study and definitive comparison with larger studies could be misleading. However, despite the severity of symptoms and the rapid progression to ARDS, H1N1 respiratory failure presents a relatively benign course when adequately treated, if compared to non-H1N1 induced ARDS, reported to have a mortality rate from 37% to 43% \[[@B19]-[@B22]\]. Several factors may account for the favourable outcome in our series. All patients received protective ventilation. In particular, ECMO support permitted the maintenance of patients under a protective tidal volume with a respiratory rate below 12 per min, and a FiO~2~below 60%, compared with non-ECMO patients who needed a higher respiratory rate and FiO~2~to maintain an acceptable pulmonary gas exchange.

The availability of easily accessible tools for pulmonary mechanics evaluations on modern ventilators allowed an individualized and appropriate setting of ventilation pressure within the thresholds of so called \"protective ventilation\" \[[@B23]\]. Furthermore, early access to ECMO resource allowed the maintenance of protective ventilation even in more severe patients (Table [4](#T4){ref-type="table"}). In this regard, lactate dehydrogenase is commonly considered a marker of lung damage, and in H1N1 pneumonia is reported as high \[[@B1]\]. In our ECMO patients, lactate dehydrogenase values presented lower levels than in non-ECMO patients (445 U/L vs 627 IU/L, respectively), suggesting that in ECMO patients the reduced need of pulmonary ventilation could reduce lung ventilatory stress and enhance healing, regardless of the more impaired lung condition.

However, it is possible that, since the technique has gained popularity and experience gathered to demonstrate its feasibility, we used ECMO also in patients who might previously have been successfully treated conventionally, and this may have influenced mortality.

Moreover, more than half of our ECMO patients needed to be land-transported from other hospitals in an advanced stage of respiratory failure. This may have further encouraged an early treatment with ECMO to ensure the safest transport.

Bleeding is commonly reported during ECMO treatment \[[@B24]\], and either anticoagulation or platelet and coagulation cascade activation through oxygenator and pump is involved \[[@B25]\].

In our population bleeding also occurred more frequently in ECMO patients, and they required more transfusions compared to non ECMO patients. Nevertheless, in our experience, bleeding from cannulas insertion site or from upper airways, despite requiring transfusion, were not life threatening, and could be managed. In only two cases did severe bleeding occur in the lower respiratory tract. Fortunately in one case it occurred during weaning from ECMO, and it ceased after extracorporeal support removal. The other patient died from pulmonary aspergillosis and the haemorrhage could be also related to parenchyma disruption caused by the fungus.

Monitoring heparin regimen is extremely important during extracorporeal circulation, and activated clotted time is commonly measured bedside. Some debate exists regarding the optimal range and the accuracy of point-of-care measuring devices \[[@B26]-[@B28]\]. In our protocol, we usually measured aPTT every two hours with Hemochron Jr. in order to closely monitor heparin administration in the low range of dosage.

In our clinical practice, lung recovery and response to treatment are daily assessed by LUS examination, following several recent reports which underline the reliability of LUS in the evaluation and management of chest disorders \[[@B10],[@B29]\]. Despite CT-scan is the reference technique for evaluating lung lesions, it requires a transitory disconnection of the patient from the ventilator to permit the transportation radiology suite with potential risk of alveolar de-recruitment and worsening of oxygenation. Moreover, severe complications have been reported in intra-hospital transportation of critically ill patients \[[@B30],[@B31]\]. As we recently reported \[[@B13]\], the routine use of bedside LUS has significantly reduce of the number of CT-scan and chest X-ray examinations in critical patients. The potential clinical benefit of reducing in-hospital transport for diagnostic radiology, it can be particularly relevant in patients with ECMO. In these patients, in fact, transportation requires time and a significant commitment of resources, although it was proved feasible both for in-hospital \[[@B32],[@B33]\] and for inter-hospital long distance transportations \[[@B34],[@B35]\].

Another advantage of LUS is the ability to evaluate the effectiveness of alveolar recruitment manoeuvres with the possibility to visualize real-time imagines of lung parenchyma re-aeration \[[@B8],[@B10],[@B29]\]. Finally, pleural effusions can be accurately diagnosed and monitored with LUS and in case of need for treatment an ultra-sound guided technique is recommended \[[@B36],[@B13]\]. This option seems to be particularly appropriate ECMO patients, where bleeding for conventional chest tube placement can occur in consideration of the need of heparin infusion.

Conclusions
===========

The present case series comprises a small number of patients, and naturally, it cannot be considered a high grade of evidence trial. However, our experience might be helpful for intensivists challenging H1N1-induced ARDS. For H1N1 infection monitoring (or diagnosis, if patient was intubated before) bronchoalveolar lavage can be more reliable than pharyngeal swab in order of the higher sensitivity. In our clinical practice, ECMO therapy resulted safe and feasible in the context of a life threatening condition, and it might be taken into consideration as a therapeutic choice rather than a rescue solution in experienced centers.

Key messages
============

• ECMO might be taken into consideration as a safe therapeutic choice rather than a rescue solution in ARDS.

• RT-PCR from bronchial lavage is more accurate than from pharyngeal swab, in H1N1 diagnosis.

• Lung ultrasonography is a safe and reliable method to follow the pathology evolution/recovery of lung.

• Lung ultrasonography can limit the need of CT-scan and chest X-ray examinations.
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